B+
Bull case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
TARA
Protara TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-03
Recent news sentiment (30D)
-0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+92.2
Score
AI commentary
The evidence supports a cautious monitoring view. The latest company filing preserves several 4Q 2026 milestones and a stated cash runway, but the recent earnings miss, low coverage, lack of dependable analyst revision data, binary clinical risk, and limited direct peer evidence argue against a high-conviction bullish stance. Social and options data are unavailable; the neutral placeholder values are not treated as evidence.
RankAlpha Sentiment Codex - 2026-09-03
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30catalystPost-Q2 earnings digestion remains a near-term overhangHigh impact
Stored earnings context reported a Q2 loss of $0.36 per share versus a $0.33 analyst estimate, leaving near-term sentiment vulnerable despite continued pipeline progress [#PR-EARNINGS-2026-08-11].
2026-12-02eventADVANCED-2 enrollment and ADVANCED-3 redesign milestonesHigh impact
Protara expects to complete enrollment of the BCG-unresponsive ADVANCED-2 registrational cohort in 4Q 2026 and is redesigning ADVANCED-3 as a broader exploratory study. Execution could improve confidence in the NMIBC program, while delay or weaker data would reinforce the wait-and-see stance [#SEC-8K-2026-08-11].
2026-12-02eventTHRIVE-3 interim resultsHigh impact
The company remains on track to report interim results from the registrational THRIVE-3 trial of IV Choline Chloride in 4Q 2026, creating a potentially material but binary clinical readout [#SEC-8K-2026-08-11].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-03 • Updated nightlySource: Internal modelMethodology